Sangamo Therapeutics, Inc.

At Sangamo, we are using #GenomicMedicine to target the underlying genetic causes of disease. Targeting these conditions at the 🧬 level may enable fine-tuning of gene expression and potentially reduce therapeutic complexity. In our latest edition of the “From the (Gene) Editor” newsletter, we invite you to read how we are leveraging the promising combination of our capsid and cargo technologies to potentially deliver therapeutic solutions, possibly transforming the landscape of genetic medicine. #genomicmedicine #neurology #zincfinger

Today we announce important second quarter financial results and key business updates, including a global epigenetic regulation and capsid delivery license agreement with Genentech, reporting of Pfizer’s positive topline results from the Phase 3 AFFINE trial in hemophilia A, and updates on other key business developments.  Learn more here: https://bit.ly/3WyTSkM #genomicmedicine #neurology #epigenetics #zincfinger

Today we are excited to announce a global epigenetic regulation and capsid delivery license agreement with Genentech to develop novel genomic medicines for neurodegenerative diseases. Sangamo has granted Genentech an exclusive license to our proprietary zinc finger repressors that are directed to the tau gene, which is critically involved in Alzheimer’s disease and other tauopathies, as well as an undisclosed second neurology target. Additionally, Sangamo has granted Genentech an exclusive license – for these same targets – to our industry-leading neurotropic delivery capsid, STAC-BBB, which has demonstrated potent blood-brain barrier penetration and brain transduction in nonhuman primates. We are excited to share this powerful combination of assets with Genentech as we seek to address devastating neurological diseases. We expect to receive $50 million in near-term upfront license fees and milestone payments and are eligible to earn up to $1.9 billion in additional milestone payments, plus tiered royalties on net sales. Learn more here: https://bit.ly/4fwrN69 #genomicmedicine #neurology #epigenetics #zincfinger

Our Q2 financial results will be announced on Tuesday, August 6, 2024, with a conference call at 4:30 PM ET. Details on how to join our conference call and webcast: https://bit.ly/46tYbCm

Today we are thrilled to share positive topline results from the pivotal Phase 3 AFFINE trial, evaluating the gene therapy candidate we are co-developing with and licensing to Pfizer for the treatment of adults with moderately severe to severe hemophilia A.  The giroctocogene fitelparvovec trial met primary and key secondary objectives of superiority compared to prophylaxis. These impressive results further validate the power of our genomic technologies and take us one step closer towards what could become Sangamo’s first medicine commercially available to patients.  Learn more here: https://bit.ly/3YgTRUV #genomicmedicine #hemophiliaA

We are excited to share an article from Science Magazine confirming the power of Sangamo’s zinc fingers for editing in the brain, click here to view it, bit.ly/3W2Apd9. The authors demonstrate that Sangamo's previously published prion zinc fingers were superior to other platforms and enabled Neumann et al to test their new epigenetic editing tool. We are proud to have pioneered the zinc finger technology that continues to lead the field of epigenetic editing. These compact, flexible tools can precisely target DNA, enhancing our potential therapies for neurological diseases including prion disease. Our zinc finger-based prion program, ST-504, is advancing towards the clinic enabled by our proprietary STAC-BBB capsid. Learn more about our whole brain delivery solution by clicking on the links below. Whole brain delivery solution, https://bit.ly/3tH18AH STAC-504, https://bit.ly/3RLFpjI STAC-BBB, https://bit.ly/3xKCWiz #GenomicMedicine #neurology #zincfinger #prion

Join CEO Sandy Macrae, MRCP PhD for a fireside chat at H.C. Wainwright & Co., LLC 5th Annual Neuro Perspectives Virtual Conference on Thursday, June 27th at 7:00 AM EDT. For the latest information, visit our website: https://bit.ly/3qc7SyU #GenomicMedicine #Neurology

One of our lead scientists, Jeffrey Miller is presenting @FASEB Genome Engineering Conference about our exciting Modular Integrase (MINT) platform - a new approach for targeted integration of large 🧬constructs into precise locations within the human genome. Jeff will share how we have successfully reprogrammed the specificity of Bxb1 Integrase, directing it to clinically relevant sites in the human genome without using CRISPR, zinc fingers, or TALE effectors. Jeff is presenting on Monday, June 17th at 4:35 p.m. CET #MINTplatform #genomicmedicine #neurology #integrases #recombinases

Join CEO Sandy Macrae, MRCP PhD for a fireside chat at Jefferies Global Healthcare Conference on Thursday, June 6th at 7:30 AM EDT. For the latest information, visit our website: https://bit.ly/3sfJt2f #GenomicMedicine #Neurology

Join this webinar on Tuesday, June 11, 2024, at 9:00 a.m. PDT to hear from the authors Yanmei Lu, Kennon Daniels, Ph.D. Marina Falaleeva on the advancements in gene therapy from a Wiley Publishing book titled "Drug Development for Gene Therapy: Translational Biomarkers, Bioanalysis, and Companion Diagnostics." This is a great opportunity to get an in-depth understanding of drug development for AAV gene therapy from subject matter experts and key opinion leaders in this space. The webinar will focus on: • An overview of the book and biomarkers for AAV gene therapy • Detection and quantification of genome editing events in preclinical and clinical studies • Companion diagnostics for AAV gene therapy • Conclusion and Q&A panel discussion Webinar Details: Pre-register for the webinar by clicking here: https://bit.ly/3wPxv1E When: Jun 11, 2024 at 9:00 AM Pacific Time (US and Canada) Panelists: Boris Gorovits, Non-clinical and Clinical Bioanalysis, Regeneron Yanmei Lu, Biomarker and BioAnalytical Sciences, Sangamo Therapeutics Wibke Lembke, Bioanalytical Services, Celerion Switzerland AG Vibha Jawa, Clinical Pharmacology, Pharmacometrics and Bioanalysis (CPPB), Bristol Myers Squibb Bonnie Wu, Biologics Discovery and Development Sciences, Johnson & Johnson Innovative Medicine Russell K. Soon Jr., BioMarin Pharmaceutical, Inc. Robert Dodge, PhD, Department of BioMedical Research, Novartis Liching Cao, Biomarker and BioAnalytical Sciences, Sangamo Therapeutics John Lin, Bioanalytical and Biologics Services, Frontage Laboratories Venkata Vepachedu, Preclinical Sciences and Translational Safety, Johnson and Johnson Innovative Medicine Magdalena Tary-Lehmann, M.D., Ph.D.-Lehmann, CTL-Contract Laboratory, Cellular Technology Limited Marina Falaleeva, Nonclinical Department, Sangamo Therapeutics Kathleen Meyer, Nonclinical Department, Sangamo Therapeutics Kennon Daniels, Ph.D. Daniels, Precision for Medicine Michael Havert, Gene Therapy Partners, LLC.